The Filing Desk

BridgeBio Pharma vs HUTCHMED (China)

BridgeBio Pharma BBIO · HUTCHMED (China) HCM · Pharmaceuticals

HUTCHMED (China) reported revenue of $548 million in fiscal 2025, about the same as BridgeBio Pharma's $502 million in fiscal 2025. BridgeBio Pharma's revenue grew 126.3% in its latest year, and HUTCHMED (China)'s fell 13.0%. BridgeBio Pharma had an operating margin of -104.2%, against -7.1% at HUTCHMED (China). Free cash flow was −$447 million at BridgeBio Pharma and −$79 million at HUTCHMED (China).

Side by side

BridgeBio PharmaHUTCHMED (China)
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$502M$548M
Revenue growth126.3%−13.0%
Revenue growth a year, last 5 years127.7%19.2%
Gross margin95.8%38.7%
Operating margin−104.2%−7.1%
Net margin−146.0%83.3%
Free cash flow−$447M−$79M
Free cash flow margin−89.0%−14.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$48M$0M
Change in diluted share count2.9%0.0%
Last close$78.18$13.45
P/E at the last close——
Insider trades, last 12 monthssold $86.2 million—
Piotroski F-score3 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BridgeBio PharmaHUTCHMED (China)
Operating margin
Percent of revenue
BridgeBio PharmaHUTCHMED (China)
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BridgeBio PharmaHUTCHMED (China)

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BridgeBio Pharma and HUTCHMED (China) pages.